Geneva, Switzerland, 10 September 2014 – Novimmune announces today that it has appointed Adrian Mills as the Company's Chief Business Officer and member of the Executive Committee (EC), with immediate effect. Adrian will be leading Novimmune's commercial development activities as well as Business Development. David Slack, Head of Corporate and Business Development, is leaving Novimmune to focus on opportunities outside the Company.
Jack Barbut, Chief Executive Officer of Novimmune, commented: "I am pleased to welcome Adrian as Chief Business Officer. He brings over 20 years of experience as a pharmaceutical executive with a particular focus on the commercialization of orphan drugs."
Adrian Mills is a British citizen joining Novimmune from GlaxoSmithKline plc (GSK), where he held various strategic and operational positions from 2000 until 2013 in Europe and SE Asia. Most recently Adrian was European Commercial Director for Rare and Critical Diseases. Prior to GSK, Adrian worked in management consulting and investment banking in the life sciences sector. He holds an MBA from the London Business School and an MA (Hons) Engineering from Queens' College, Cambridge.
Thanking David Slack for his contribution, Jack Barbut said: "David has made a valuable contribution to our business development efforts and in general at the Executive Team level. We wish him every success for his future".